New combo therapy aims to boost lung cancer treatment
Disease control
Recruiting now
This study tests an experimental drug called STK-012, alone or with standard chemotherapy, in people with advanced solid tumors, especially a type of lung cancer called non-small cell lung cancer (NSCLC). The goal is to see if adding STK-012 helps shrink tumors better than standa…
Phase: PHASE1, PHASE2 • Sponsor: Synthekine • Aim: Disease control
Last updated May 17, 2026 01:48 UTC